(Q33378620)

26 July 2017

1 reference

title

Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks (English)

1 reference

26 July 2017

1 reference

Laurent Sailler

1

1 reference

26 July 2017

publication date

1 February 2008

1 reference

Clinical Reviews in Allergy & Immunology

26 July 2017

published in

1 reference

26 July 2017

volume

34

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

103-110

1 reference

https://scigraph.springernature.com/pub.10.1007/s12016-007-8020-7

26 July 2017

exact match

0 references

cites work

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

1 reference

12 December 2020

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

1 reference

12 December 2020

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases

1 reference

12 December 2020

Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

1 reference

12 December 2020

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome

1 reference

12 December 2020

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

1 reference

12 December 2020

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

1 reference

12 December 2020

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

12 December 2020

Rituximab in autoimmune bullous diseases: mixed responses and adverse effects

1 reference

12 December 2020

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

1 reference

12 December 2020

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

12 December 2020

The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

1 reference

12 December 2020

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

1 reference

12 December 2020

Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia

1 reference

12 December 2020

Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease

1 reference

12 December 2020

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

1 reference

12 December 2020

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

1 reference

12 December 2020

The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders

1 reference

12 December 2020

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

12 December 2020

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

1 reference

12 December 2020

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab

1 reference

12 December 2020

Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.

1 reference

12 December 2020

Rituximab in the treatment of refractory autoimmune cytopenias in adults.

1 reference

12 December 2020

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

12 December 2020

Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood

1 reference

12 December 2020

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

1 reference

12 December 2020

Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients

1 reference

12 December 2020

Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients

1 reference

12 December 2020

Rituximab as therapy for refractory polymyositis and dermatomyositis.

1 reference

12 December 2020

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

1 reference

12 December 2020

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

12 December 2020

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients

1 reference

12 December 2020

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

1 reference

12 December 2020

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20

1 reference

12 December 2020

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

1 reference

12 December 2020

Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations

1 reference

12 December 2020

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications

1 reference

12 December 2020

Rituximab therapy for childhood-onset systemic lupus erythematosus

1 reference

12 December 2020

Tolerability and safety of rituximab (MabThera).

1 reference

12 December 2020

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome

1 reference

12 December 2020

Rituximab in refractory autoimmune bullous diseases.

1 reference

12 December 2020

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

1 reference

12 December 2020

Response to rituximab in patients with type II cryoglobulinemia

1 reference

12 December 2020

10.1007/S12016-007-8020-7

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1045736008

0 references

1 reference